Literature DB >> 17371961

Natural and synthetic TLR7 ligands inhibit CpG-A- and CpG-C-oligodeoxynucleotide-induced IFN-alpha production.

Beate Berghöfer1, Gabriela Haley, Ture Frommer, Gregor Bein, Holger Hackstein.   

Abstract

Plasmacytoid dendritic cells (pDCs) are unique with respect to their capacity to produce unsurpassed amounts of IFN-alpha and coexpress TLR7 and TLR9, mediating IFN-alpha production. Although TLRs are critical receptors of innate immunity, little is known about the immunological effects of TLR7/TLR9 costimulation. We have analyzed the effects of TLR7/TLR9 costimulation on IFN-alpha production by leukocytes and pDCs. Our experiments revealed that both synthetic (resiquimod and loxoribine) and natural (ssRNA40) TLR7 ligands abrogate CpG-A- and CpG-C-oligodeoxynucleotide (ODN)-induced IFN-alpha production by human leukocytes. Because TLR7 ligands themselves represent important IFN-alpha inducers, we demonstrated that substimulatory TLR7 ligand concentrations significantly inhibited CpG-A-induced IFN-alpha. Delayed addition of TLR7 ligands still resulted in complete suppression of CpG-A-ODN-induced IFN-alpha production, suggesting that the inhibition is unlikely to be caused by a kinetic uptake advantage. Unlike for CpG-A and CpG-C, TLR7 ligands did not inhibit CpG-B-ODN-induced IFN-alpha production. Experiments with purified human pDCs demonstrated that the inhibitory effects of TLR7/TLR9 costimulation were mediated directly by pDCs. Suppression of IFN-alpha production was not related to increased cell death and was also detectable in enriched mouse pDCs. Analyses of pDCs suggested that the TLR7 signal regulates the outcome of TLR7 ligand/CpG-A-ODN costimulation and can either inhibit (IFN-alpha) or promote (IL-8/CD40) cytokine and surface marker expression. Our data reveal for the first time a strong inhibitory effect of TLR7 stimulation on IFN-alpha production induced by CpG-A- and CpG-C-ODNs. These findings provide novel insight into the effects of TLR7/TLR9 costimulation and may support the development of novel TLR9 inhibitors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17371961     DOI: 10.4049/jimmunol.178.7.4072

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  23 in total

Review 1.  Self-regulation and cross-regulation of pattern-recognition receptor signalling in health and disease.

Authors:  Xuetao Cao
Journal:  Nat Rev Immunol       Date:  2016-01       Impact factor: 53.106

2.  Platelet-TLR7 mediates host survival and platelet count during viral infection in the absence of platelet-dependent thrombosis.

Authors:  Milka Koupenova; Olga Vitseva; Christopher R MacKay; Lea M Beaulieu; Emelia J Benjamin; Eric Mick; Evelyn A Kurt-Jones; Katya Ravid; Jane E Freedman
Journal:  Blood       Date:  2014-04-22       Impact factor: 22.113

3.  Differential regulation of toll-like receptor pathways in acute and chronic HIV-1 infection.

Authors:  J Judy Chang; Aurore Lacas; Robert J Lindsay; Erin H Doyle; Karen L Axten; Florencia Pereyra; Eric S Rosenberg; Bruce D Walker; Todd M Allen; Marcus Altfeld
Journal:  AIDS       Date:  2012-03-13       Impact factor: 4.177

4.  Interactions between TLR7 and TLR9 agonists and receptors regulate innate immune responses by astrocytes and microglia.

Authors:  Niranjan B Butchi; Min Du; Karin E Peterson
Journal:  Glia       Date:  2010-04-15       Impact factor: 7.452

5.  Migration of dendritic cells from murine skeletal muscle.

Authors:  Lei Wang; Saman Eghtesad; Paula R Clemens
Journal:  Immunobiology       Date:  2010-05-21       Impact factor: 3.144

6.  Dual activation of Toll-like receptors 7 and 9 impairs the efficacy of antitumor vaccines in murine models of metastatic breast cancer.

Authors:  Mariela A Moreno Ayala; María Florencia Gottardo; María Soledad Gori; Alejandro Javier Nicola Candia; Carla Caruso; Andrea De Laurentiis; Mercedes Imsen; Slobodanka Klein; Elisa Bal de Kier Joffé; Gabriela Salamone; Maria G Castro; Adriana Seilicovich; Marianela Candolfi
Journal:  J Cancer Res Clin Oncol       Date:  2017-04-21       Impact factor: 4.553

7.  Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG.

Authors:  Jasper G van den Boorn; Debby Konijnenberg; Esther P M Tjin; Daisy I Picavet; Nico J Meeuwenoord; Dmitri V Filippov; J P Wietze van der Veen; Jan D Bos; Cornelis J M Melief; Rosalie M Luiten
Journal:  PLoS One       Date:  2010-05-13       Impact factor: 3.240

8.  Visualization of IFNbeta production by plasmacytoid versus conventional dendritic cells under specific stimulation conditions in vivo.

Authors:  Stefanie Scheu; Philipp Dresing; Richard M Locksley
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-16       Impact factor: 11.205

9.  Reduced IgG anti-small nuclear ribonucleoprotein autoantibody production in systemic lupus erythematosus patients with positive IgM anti-cytomegalovirus antibodies.

Authors:  Claudia Azucena Palafox Sánchez; Minoru Satoh; Edward Kl Chan; Wendy C Carcamo; José Francisco Muñoz Valle; Gerardo Orozco Barocio; Edith Oregon Romero; Rosa Elena Navarro Hernández; Mario Salazar Páramo; Antonio Cabral Castañeda; Mónica Vázquez Del Mercado
Journal:  Arthritis Res Ther       Date:  2009-02-20       Impact factor: 5.156

10.  A class C CpG toll-like receptor 9 agonist successfully induces robust interferon-alpha production by plasmacytoid dendritic cells from patients chronically infected with hepatitis C.

Authors:  N A Libri; S J Barker; W M C Rosenberg; A E Semper
Journal:  J Viral Hepat       Date:  2009-02-24       Impact factor: 3.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.